<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154542">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01687491</url>
  </required_header>
  <id_info>
    <org_study_id>AXA_2012</org_study_id>
    <nct_id>NCT01687491</nct_id>
  </id_info>
  <brief_title>Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome</brief_title>
  <acronym>AXA</acronym>
  <official_title>Comparison of Anti-Xa Activity in the Treatment With Enoxaparin in ACS Admitted to the Emergency. Randomized Clinical Trial ENOXA ® Versus LOVENOX ®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Les Laboratoires des Médicaments Stériles</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>emergency department of the hospital  Fattouma Bourguiba Monastir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Division of Hematology of the hospital  Fattouma Bourguiba Monastir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Les Laboratoires des Médicaments Stériles</source>
  <oversight_info>
    <authority>Tunisia: Office of Pharmacies and Medicines</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a clinical trial monocentric, open, randomized ENOXA ® versus LOVENOX ®,
      conducted on two parallel groups of patients admitted in emergency for acute coronary
      syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients included in this study with an acute coronary Syndrome be admitted to the
      emergency room and receive treatment with enoxaparin. Low molecular weight heparin (LMWH)
      treatment in this indication is usually spread over a week. The experience of the study
      intends to focus only on the first injection administered in selected patients.

      Two assays are carried out, including an assessment of the anti-Xa activity initially before
      injection of enoxaparin, and 4 hours after administration of the first syringe.

      Clinical monitoring is intrahospital from the date of hospitalization of patients included
      until emergency exit (transfer to another service, or return home)

      Tolerance assessment (clinical and biological) is performed during follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>anti-Xa activity</measure>
    <time_frame>4 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>assay of anti-Xa activity 4 hours after the first injection énoxparine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Tolerance is assessed by the occurrence of adverse events and / or serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Factor X</condition>
  <arm_group>
    <arm_group_label>Enoxa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ENOXA® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovenox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LOVENOX® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENOXA®</intervention_name>
    <arm_group_label>Enoxa</arm_group_label>
    <other_name>ENOXA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOVENOX®</intervention_name>
    <arm_group_label>Lovenox</arm_group_label>
    <other_name>LOVENOX®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over the age of 20 years

          -  acute coronary syndrome

          -  Admission to the emergency department

        Exclusion Criteria:

          -  Patient participating in another study

          -  Pregnant or lactating or of childbearing potential not using medically accepted
             method of contraception

          -  Taking an anticoagulant in the last three months

          -  Patient with known haemostatic disorder

          -  Contraindication absolute and / or relative to the use of enoxaparin

          -  Nobody wishing to participate in this study or not having the ability to understand
             its objectives
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Semir Nouira, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Fattouma Bourguiba Hospital, Monastir</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohsen Hassine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fattouma Bourguiba, Monastir</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sémir Nouira, PHD</last_name>
    <phone>+216 73 425 265</phone>
    <email>semir.nouira@rns.tn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohsen Hassine, PHD</last_name>
    <phone>+216 98 277 139</phone>
    <email>mohsen.hassine@rns.tn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Departement of Emergency</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Semir Nouira, PHD</last_name>
      <phone>+216 73 425 265</phone>
      <email>semir.nouira@rns.tn</email>
    </contact>
    <contact_backup>
      <last_name>Mohsen Hassine</last_name>
      <phone>+216 98 277 139</phone>
      <email>mohsen.hassine@rns.tn</email>
    </contact_backup>
    <investigator>
      <last_name>Semir Nouira, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 18, 2012</lastchanged_date>
  <firstreceived_date>September 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enoxaparin</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Factor X</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
